Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results
Interpace Biosciences (IDXG) reported preliminary Q4 and full-year 2024 results, highlighting record-breaking performance across key metrics. The company achieved a 21% year-over-year increase in Q4 Molecular Volume and a 17% increase for the full year, leading to double-digit revenue growth in both periods.
The company reached all-time highs in test volume, revenue, income, and cash collections for both Q4 and FY2024. Their ThyGeNEXT® + ThyraMIR®v2 testing services for indeterminate thyroid nodules showed particularly strong physician demand, significantly contributing to profitability.
While maintaining a positive outlook for 2025, management acknowledged uncertainty regarding PancraGEN® Medicare reimbursement, but indicated preparedness for potential non-coverage determination, emphasizing the strength and profitability of their Endo business unit as a solid foundation.
Interpace Biosciences (IDXG) ha riportato risultati preliminari per il quarto trimestre e per l'intero anno 2024, evidenziando prestazioni da record in tutti i principali indicatori. L'azienda ha registrato un aumento del 21% anno su anno nel volume molecolare del Q4 e un aumento del 17% per l'intero anno, portando a una crescita dei ricavi a doppia cifra in entrambi i periodi.
L'azienda ha raggiunto livelli storici nel volume dei test, nei ricavi, nei profitti e nelle riscossioni per il quarto trimestre e per l'anno fiscale 2024. I loro servizi di test ThyGeNEXT® + ThyraMIR®v2 per noduli tiroidei indeterminati hanno mostrato una domanda particolarmente forte da parte dei medici, contribuendo significativamente alla redditività.
Mantenendo un outlook positivo per il 2025, la direzione ha riconosciuto l'incertezza riguardo il rimborso Medicare per PancraGEN®, ma ha indicato una preparazione per una possibile determinazione di non copertura, sottolineando la forza e la redditività della loro unità di business Endo come solida base.
Interpace Biosciences (IDXG) reportó resultados preliminares para el cuarto trimestre y el año completo 2024, destacando un rendimiento récord en métricas clave. La empresa logró un aumento del 21% interanual en el volumen molecular del Q4 y un aumento del 17% para el año completo, lo que llevó a un crecimiento de ingresos de dos dígitos en ambos períodos.
La empresa alcanzó máximos históricos en volumen de pruebas, ingresos, ganancias y cobros en efectivo tanto para el Q4 como para el FY2024. Sus servicios de prueba ThyGeNEXT® + ThyraMIR®v2 para nódulos tiroideos indeterminados mostraron una demanda particularmente fuerte por parte de los médicos, contribuyendo significativamente a la rentabilidad.
Si bien mantiene una perspectiva positiva para 2025, la dirección reconoció la incertidumbre respecto al reembolso de PancraGEN® por Medicare, pero indicó que está preparada para una posible determinación de no cobertura, enfatizando la fortaleza y rentabilidad de su unidad de negocio Endo como una base sólida.
인터페이스 바이오사이언스 (IDXG)는 2024년 4분기 및 전체 연도 예비 결과를 보고하며 주요 지표에서 기록적인 성과를 강조했습니다. 회사는 4분기 분자 볼륨에서 전년 대비 21% 증가와 전체 연도에서 17% 증가를 달성하여 두 자릿수 수익 성장으로 이어졌습니다.
회사는 4분기와 2024 회계연도에 대한 검사량, 수익, 수익 및 현금 수금에서 사상 최고치를 기록했습니다. 불확실한 갑상선 결절을 위한 ThyGeNEXT® + ThyraMIR®v2 검사 서비스는 특히 의료진의 강력한 수요를 보여주어 수익성에 크게 기여했습니다.
2025년을 긍정적으로 전망하면서 경영진은 PancraGEN® 메디케어 환급에 대한 불확실성을 인정했지만, 비보험 결정 가능성에 대비할 준비가 되어 있다고 밝혔습니다. 또한 Endo 비즈니스 부문의 강점과 수익성을 강조하며 견고한 토대가 되고 있음을 강조했습니다.
Interpace Biosciences (IDXG) a rapporté des résultats préliminaires pour le quatrième trimestre et l'année complète 2024, soulignant des performances record dans des indicateurs clés. L'entreprise a enregistré une augmentation de 21 % du volume moléculaire d'une année sur l'autre au quatrième trimestre et une augmentation de 17 % pour l'année entière, entraînant une croissance à deux chiffres des revenus dans les deux périodes.
L'entreprise a atteint des niveaux historiques en matière de volume de tests, de revenus, de bénéfices et de recouvrements de liquidités pour le quatrième trimestre et l'exercice 2024. Ses services de test ThyGeNEXT® + ThyraMIR®v2 pour les nodule thyroïdiens indéterminés ont montré une demande particulièrement forte de la part des médecins, contribuant ainsi de manière significative à la rentabilité.
Tout en maintenant une perspective positive pour 2025, la direction a reconnu l'incertitude concernant le remboursement Medicare de PancraGEN®, mais a indiqué sa préparation à une éventuelle décision de non-coverage, soulignant la force et la rentabilité de son unité commerciale Endo comme une base solide.
Interpace Biosciences (IDXG) hat vorläufige Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 veröffentlicht, die eine rekordverdächtige Leistung in allen wichtigen Kennzahlen hervorheben. Das Unternehmen erzielte einen 21%igen Anstieg des molekularen Volumens im vierten Quartal im Vergleich zum Vorjahr und einen 17%igen Anstieg für das gesamte Jahr, was in beiden Zeiträumen zu einem zweistelligen Umsatzwachstum führte.
Das Unternehmen erreichte in den Bereichen Testvolumen, Umsatz, Gewinn und Bareinnahmen sowohl im vierten Quartal als auch im Geschäftsjahr 2024 historische Höchststände. Ihre Testdienstleistungen ThyGeNEXT® + ThyraMIR®v2 für unbestimmte Schilddrüsenknoten zeigten eine besonders starke Nachfrage von Ärzten, was erheblich zur Rentabilität beitrug.
Die Geschäftsführung äußerte sich optimistisch für 2025, erkannte jedoch die Unsicherheit bezüglich der Medicare-Erstattung für PancraGEN® an und wies darauf hin, dass sie auf eine mögliche Nichtabdeckungsvorstellung vorbereitet sind. Dabei wurde die Stärke und Rentabilität ihrer Endo-Geschäftseinheit als solide Grundlage betont.
- Record-breaking Q4 molecular test volume growth of 21% YoY
- Full-year molecular test volume growth of 17%
- All-time high test revenue, income, and cash collections
- Record gross and net income margins
- Strong performance in ThyGeNEXT® + ThyraMIR®v2 testing services
- Potential risk of PancraGEN® Medicare non-coverage determination
| ● | Q4 and FY Test volume increase | |
| ● | Q4 and FY Volume, Revenue, and Profitability at all-time record levels | |
PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced preliminary financial and business results for the fiscal year and fourth quarter ended December 31, 2024.
Fourth quarter Molecular Volume increased
“Q4 continued the Company’s trend of double-digit year-over-year volume and revenue growth fueled by the full suite of Interpace testing services. Physician demand for ThyGeNEXT® + ThyraMIR®v2, our Company’s unique mutational- and microRNA-based assay for indeterminate thyroid nodules was exceptionally high and a very strong driver of the Company’s profitability. stated Tom Burnell, President and CEO. Burnell added, “the Company completed a strong year financially in 2024 which has set the stage to continue to execute its strategy of growth in 2025. The Company understands the uncertainty surrounding PancraGEN® Medicare reimbursement going forward and, in the event of a non-coverage determination, has made plans to manage through this situation. Our Endo business unit is strong and profitable. It provides a solid foundation from which to continue our strong performance, should this situation occur.”
About Interpace Biosciences
Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Interpace provides clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has five commercialized molecular tests and one test in a clinical evaluation program (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA®, a “molecular only” version of PancraGEN that provides physicians a snapshot of a limited number of factors; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay; ThyraMIR®v2, used in combination with ThyGeNEXT®, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification; and RespriDX®, that differentiates lung cancer of primary versus metastatic origin. In addition, BarreGEN®, a molecular-based assay that helps resolve the risk of progression of Barrett’s Esophagus to esophageal cancer, is currently in a CEP, whereby we gather information from physicians using BarreGEN to assist us in gathering clinical evidence relative to the safety and performance of the test and also providing data that will potentially support payer reimbursement.
For more information, please visit Interpace Biosciences’ website at www.interpace.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements, including, but not limited to, the possibility that the Company’s estimates of future revenue, cash flows and adjusted EBITDA may prove to be materially inaccurate, the Company’s prior history of operating losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s ability to repay borrowings from BroadOak, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect, and the Company’s ability to restructure itself in light of the loss of reimbursement for its PancraGEN product.
Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as amended, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contacts:
Investor Relations
Interpace Biosciences, Inc.
(855)-776-6419
Info@Interpace.com
FAQ
What was IDXG's molecular test volume growth in Q4 2024?
How did IDXG perform in full-year 2024 test volumes?
What potential risk does IDXG face regarding Medicare reimbursement?
Which IDXG testing service showed exceptional demand in 2024?
What financial records did IDXG break in Q4 and FY 2024?
